Devonian Health Group Inc. (DVHGF)
USD 0.14
(0.0%)
USD 0.14
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 3.67 Million CAD | -14.12% |
| 2022 | 4.27 Million CAD | -18.89% |
| 2021 | 5.27 Million CAD | 12.61% |
| 2020 | 4.68 Million CAD | 5.59% |
| 2019 | 4.43 Million CAD | 15.2% |
| 2018 | 3.85 Million CAD | 18.14% |
| 2017 | 3.25 Million CAD | -40.54% |
| 2016 | 5.48 Million CAD | -1.84% |
| 2015 | 5.58 Million CAD | 0.0% |
| 2014 | - CAD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 3.66 Million CAD | -0.14% |
| 2024 Q2 | 3.7 Million CAD | 0.84% |
| 2024 Q3 | 2.18 Million CAD | -40.99% |
| 2023 Q1 | 3.59 Million CAD | -15.89% |
| 2023 Q2 | 3.68 Million CAD | 2.39% |
| 2023 FY | 3.67 Million CAD | -14.12% |
| 2023 Q3 | 3.67 Million CAD | -0.14% |
| 2023 Q4 | 3.67 Million CAD | -0.14% |
| 2022 Q2 | 5.15 Million CAD | -3.25% |
| 2022 Q4 | 4.27 Million CAD | -18.52% |
| 2022 FY | 4.27 Million CAD | -18.89% |
| 2022 Q1 | 5.32 Million CAD | 1.0% |
| 2022 Q3 | 5.25 Million CAD | 1.87% |
| 2021 Q1 | 4.75 Million CAD | 1.58% |
| 2021 FY | 5.27 Million CAD | 12.61% |
| 2021 Q4 | 5.27 Million CAD | 6.24% |
| 2021 Q3 | 4.96 Million CAD | 1.72% |
| 2021 Q2 | 4.88 Million CAD | 2.58% |
| 2020 Q3 | 4.99 Million CAD | 0.34% |
| 2020 Q4 | 4.68 Million CAD | -6.29% |
| 2020 Q2 | 4.98 Million CAD | -0.39% |
| 2020 FY | 4.68 Million CAD | 5.59% |
| 2020 Q1 | 5 Million CAD | 12.73% |
| 2019 Q4 | 4.43 Million CAD | 1.42% |
| 2019 Q2 | 4.39 Million CAD | 3.03% |
| 2019 FY | 4.43 Million CAD | 15.2% |
| 2019 Q1 | 4.26 Million CAD | 10.85% |
| 2019 Q3 | 4.37 Million CAD | -0.54% |
| 2018 Q3 | 3.9 Million CAD | 20.06% |
| 2018 Q4 | 3.85 Million CAD | -1.4% |
| 2018 FY | 3.85 Million CAD | 18.14% |
| 2018 Q2 | 3.25 Million CAD | 0.0% |
| 2018 Q1 | 3.25 Million CAD | -0.2% |
| 2017 FY | 3.25 Million CAD | -40.54% |
| 2017 Q4 | 3.25 Million CAD | -37.31% |
| 2017 Q3 | 5.19 Million CAD | -2.06% |
| 2017 Q1 | 5.42 Million CAD | -1.12% |
| 2017 Q2 | 5.3 Million CAD | -2.05% |
| 2016 Q3 | 5.36 Million CAD | 0.0% |
| 2016 FY | 5.48 Million CAD | -1.84% |
| 2016 Q2 | - CAD | 0.0% |
| 2016 Q1 | - CAD | 0.0% |
| 2016 Q4 | 5.48 Million CAD | 2.13% |
| 2015 Q1 | - CAD | 0.0% |
| 2015 Q3 | - CAD | 0.0% |
| 2015 FY | 5.58 Million CAD | 0.0% |
| 2015 Q4 | - CAD | 0.0% |
| 2014 FY | - CAD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| ContraFect Corporation | 2.88 Million USD | -27.533% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -1731.469% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -2496.292% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -173.464% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 91.083% |
| Kadimastem Ltd | 891.22 Thousand USD | -312.266% |
| Zenith Capital Corp. | 10.22 Thousand USD | -35833.692% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -921.439% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | 71.73% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -814.329% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -154.039% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 87.657% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -287.465% |
| Qrons Inc. | 351.84 Thousand USD | -944.266% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -35.645% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -53.238% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | -145.808% |
| Affymax, Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 94.568% |
| Arch Therapeutics, Inc. | 5.87 Million USD | 37.418% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | 35.066% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | 735.54 Thousand USD | -399.526% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 81.925% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -199.116% |
| CytoDyn Inc. | 30.07 Million USD | 87.784% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 91.529% |
| IMV Inc. | 28.88 Million USD | 87.279% |
| Genus plc | 233.1 Million USD | 98.424% |
| Halberd Corporation | 150 Thousand USD | -2349.48% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | 10.862% |
| LadRx Corporation | 33.6 Thousand USD | -10833.226% |
| Marizyme, Inc. | 18.71 Million USD | 80.37% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 88.9% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -2611.862% |
| Q BioMed Inc. | 4.1 Million USD | 10.603% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -385.877% |
| Enzolytics Inc. | 996.33 Thousand USD | -268.772% |
| CSL Limited | 12.18 Billion USD | 99.97% |
| Skye Bioscience, Inc. | 4.61 Million USD | 20.39% |
| SQZ Biotechnologies Company | 27.47 Million USD | 86.625% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -313.734% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -25.383% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -1502.427% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 48.051% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -389.896% |
| NovAccess Global Inc. | 2.19 Million USD | -67.019% |
| HST Global, Inc. | 98.31 Thousand USD | -3637.04% |
| SYBLEU INC | 477.5 Thousand USD | -669.47% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 93.609% |
| Alpha Cognition Inc. | 1.22 Million USD | -201.074% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Mesoblast Limited | 118.7 Million USD | 96.905% |
| MultiCell Technologies, Inc. | 202.58 USD | -1813613.101% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -57.966% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -14186.014% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -483.138% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 97.858% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -62.693% |
| GB Sciences, Inc. | 1.75 Million USD | -108.845% |
| argenx SE | 20 Million USD | 81.629% |
| Resverlogix Corp. | 6.49 Million USD | 43.395% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -1337.533% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 91.935% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -21.414% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| ONE Bio Corp. | 19.71 Million USD | 81.363% |
| Genscript Biotech Corporation | 417.73 Million USD | 99.12% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -2371.659% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -1377.252% |
| Agentix Corp. | 50 Thousand USD | -7248.44% |
| Adynxx, Inc. | - USD | -Infinity% |
| BioStem Technologies, Inc. | 4.71 Million USD | 22.015% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -1368.619% |
| Cell Source, Inc. | 9.25 Million USD | 60.297% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -385.877% |
| Itoco Inc. | 228.37 Thousand USD | -1508.84% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -1641.543% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | 26.265% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | 53.015% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -2899.363% |
| Rebus Holdings, Inc. | 310 Thousand USD | -1085.232% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | 22.408% |
| Mobile Lads Corp. | 484.28 Thousand USD | -658.691% |
| International Stem Cell Corporation | 4.17 Million USD | 12.058% |
| Bioxytran, Inc. | 1.92 Million USD | -90.869% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -5786.947% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -68.473% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | 55.817% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | 57.202% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -136.211% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -1270.978% |
| Neutra Corp. | 54.15 Thousand USD | -6684.511% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -100.777% |
| PureTech Health plc | 25.51 Million USD | 85.598% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -200.126% |
| IXICO plc | 472.02 Thousand USD | -678.399% |
| IntelGenx Technologies Corp. | 15.5 Million USD | 76.297% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 94.099% |
| CSL Limited | 12.18 Billion USD | 99.97% |
| Cellectis S.A. | 92.77 Million USD | 96.04% |